Back to Search
Start Over
Appropriate use of bendamustine in first-line therapy of chronic lymphocytic leukemia. Recommendations from SIE, SIES, GITMO Group
- Source :
- Leukemia research. 38(11)
- Publication Year :
- 2014
-
Abstract
- By using the GRADE system we produced the following recommendations for the use of bendamustine in the first-line treatment of CLL: (1) bendamustine with rituximab is recommended in elderly fit patients potentially eligible to FCR; (2) Bendamustine alone is recommended in patients who are candidate to chlorambucil alone; (3) Rituximab–bendamustine is recommended in patients not eligible to FCR, but suitable to receive rituximab. Consensus-based recommendations addressed evidence-orphan issues concerning the use of bendamustine in genetically-defined high-risk patients and the appropriate dose of bendamustine as single agent or in association with rituximab.
- Subjects :
- Oncology
Bendamustine
Cancer Research
medicine.medical_specialty
Chronic lymphocytic leukemia
Guidelines
therapeutic use, Humans, Leukemia
Appropriate use
Antineoplastic Agent
First line therapy
immune system diseases
hemic and lymphatic diseases
Internal medicine
medicine
Bendamustine Hydrochloride
Humans
Single agent
Chronic
Antineoplastic Agents, Alkylating
drug therapy, Nitrogen Mustard Compound
Chlorambucil
business.industry
Grade system
B-Cell
First line treatment
Hematology
medicine.disease
Alkylating
Bendamustine, Chronic lymphocytic leukemia, First line treatment, Guidelines
Leukemia, Lymphocytic, Chronic, B-Cell
Lymphocytic
Settore MED/15 - MALATTIE DEL SANGUE
therapeutic use
Immunology
Nitrogen Mustard Compounds
Rituximab
business
medicine.drug
Subjects
Details
- ISSN :
- 18735835
- Volume :
- 38
- Issue :
- 11
- Database :
- OpenAIRE
- Journal :
- Leukemia research
- Accession number :
- edsair.doi.dedup.....d1e379882e010c1f38896ee260b691c5